Published in N Engl J Med on July 21, 1994
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest (1998) 2.54
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med (2014) 2.23
Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol (2003) 2.06
Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis (2013) 1.67
Langerhans cell histiocytosis. Skeletal Radiol (2006) 1.62
Demonstration of an osteoblast defect in two cases of human malignant osteopetrosis. Correction of the phenotype after bone marrow transplant. J Clin Invest (1996) 1.57
Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis (2012) 1.54
Genetic control of X inactivation and processes leading to X-inactivation skewing. Am J Hum Genet (1996) 1.42
Solitary langerhans histiocytosis of the thyroid gland: a case report and literature review. Head Neck Pathol (2011) 1.39
Detection of clonal histiocytes in Langerhans cell histiocytosis: biology and clinical significance. Br J Cancer Suppl (1994) 1.35
B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One (2012) 1.29
Circulating human dendritic cells differentially express high levels of a 55-kd actin-bundling protein. Am J Pathol (1996) 1.21
Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med (2007) 1.10
Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med (2003) 1.10
The normal Langerhans cell and the LCH cell. Br J Cancer Suppl (1994) 1.06
The histopathology of Langerhans cell histiocytosis. Br J Cancer Suppl (1994) 1.05
Adult pulmonary Langerhans' cell histiocytosis. Thorax (2000) 0.99
Systemic Erdheim-Chester disease. Virchows Arch (2008) 0.97
Evaluation of clonal origin of malignant mesothelioma. J Transl Med (2014) 0.96
Desmoids in familial adenomatous polyposis are monoclonal proliferations. Br J Cancer (2000) 0.96
A rare occurrence of Langerhans cell histiocytosis in an adult. J Oral Maxillofac Pathol (2015) 0.95
Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases. Adv Immunol (2013) 0.95
Langerhans cell histiocytosis: malignancy or inflammatory disorder doing a great job of imitating one? Dis Model Mech (2009) 0.95
DNA repeats--a treasury of human variation. N Engl J Med (1994) 0.94
Radiotherapy in langerhans cell histiocytosis - a rare indication in a rare disease. Radiat Oncol (2013) 0.93
Nonrandom X-chromosome inactivation in hemopoietic cells from carriers of dyskeratosis congenita. Am J Hum Genet (1997) 0.92
Solitary Type of Congenital Self-healing Reticulohistiocytosis. Ann Dermatol (2011) 0.92
Langerhans cell histiocytosis of the orbit: five clinicopathologic cases and review of the literature. Surv Ophthalmol (2012) 0.92
Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol (2014) 0.90
MRI and clinical features of Langerhans cell histiocytosis (LCH) in the pelvis and extremities: can LCH really look like anything? Skeletal Radiol (2016) 0.90
Evidence for clonal origin of neoplastic neuronal and glial cells in gangliogliomas. Am J Pathol (1997) 0.90
An unusual case of Erdheim-Chester disease with features of Langerhans cell histiocytosis. Skeletal Radiol (2007) 0.90
Novel endogenous type D retroviral particles expressed at high levels in a SCID mouse thymic lymphoma. J Virol (1999) 0.90
Clonality in Langerhans' cell histiocytosis. BMJ (1995) 0.89
Langerhan's cell histiocytosis complicating small bowel Crohn's disease. Gut (1996) 0.89
Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis. Cell Commun Signal (2015) 0.87
Expression of cellular adhesion molecules in Langerhans cell histiocytosis and normal Langerhans cells. Am J Pathol (1995) 0.85
Cytogenetic abnormalities in Langerhans cell histiocytosis. Br J Cancer (1998) 0.85
Pseudotumors and tumors of the temporomandibular joint. A review. Med Oral Patol Oral Cir Bucal (2013) 0.83
Role of granulocyte-macrophage colony stimulating factor (GM-CSF) in the pathogenesis of adult pulmonary histiocytosis X. Thorax (1996) 0.83
New insights into the molecular pathogenesis of langerhans cell histiocytosis. Oncologist (2014) 0.83
Late recurrence of Langerhans cell histiocytosis in the orbit. Br J Ophthalmol (2004) 0.82
Erdheim-Chester disease of the breast associated with Langerhans-cell histiocytosis of the hard palate. Virchows Arch (2004) 0.81
Langerhans cells in Langerhans cell granulomatosis are not actively proliferating cells. Am J Pathol (1998) 0.81
Management of eosinophilic granuloma occurring in the appendicular skeleton in children. Clin Orthop Surg (2009) 0.80
A novel, essential control for clonality analysis with human androgen receptor gene polymerase chain reaction. Am J Pathol (2002) 0.80
Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr (2014) 0.80
IL-17A receptor expression differs between subclasses of Langerhans cell histiocytosis, which might settle the IL-17A controversy. Virchows Arch (2012) 0.79
Growth hormone replacement in patients with Langerhan's cell histiocytosis. Arch Dis Child (1998) 0.79
Langerhans cell histiocytosis (histiocytosis X). Postgrad Med J (1997) 0.79
Multisystem Langerhans' cell histiocytosis (Hand-Schüller-Christian disease) in an adult: a case report and review of the literature. Eur Arch Otorhinolaryngol (2003) 0.79
Solitary Langerhans cell histiocytosis of frontal lobe: a case report and literature review. Chin J Cancer Res (2014) 0.78
Presence of circulating abnormal CD34+ progenitors in adult Langerhans cell histiocytosis. Clin Exp Immunol (1999) 0.78
Mastocytosis: reactive or neoplastic? J Clin Pathol (1997) 0.78
Cell(s) of Origin of Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am (2015) 0.78
[Histiocytic diseases in childhood and adolescence]. Pathologe (2015) 0.77
Differential Expression of Markers in Extensive and Restricted Langerhans Cell Histiocytosis (LCH). Pathol Oncol Res (1996) 0.77
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester disease in adults. Blood (2017) 0.76
Thigh pain in a 53-year-old woman. Clin Orthop Relat Res (2008) 0.76
Langerhans cell histiocytosis and choledocholithiasis: is there an association? Gastroenterol Hepatol (N Y) (2012) 0.75
Langerhans cell histiocytosis in Chinese adults: absence of BRAF mutations and increased FOXP3(+) regulatory T cells. Int J Clin Exp Pathol (2014) 0.75
Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics. Clin Proteomics (2015) 0.75
The scientific challenge of Langerhans cell histiocytosis. Br J Cancer Suppl (1994) 0.75
Successful outcome of Langerhans cell histiocytosis complicated by therapy-related myelodysplasia and acute myeloid leukemia: a case report. Cases J (2008) 0.75
Langerhans' cell histiocytosis involving posterior elements of the dorsal spine: An unusual cause of extradural spinal mass in an adult. J Craniovertebr Junction Spine (2011) 0.75
Bone marrow infiltration in Langerhan's cell histiocytosis - An unusual but important determinant for staging and treatment. Int J Hematol Oncol Stem Cell Res (2015) 0.75
Langerhans' Cell Histiocytosis - Case Report. Med J Armed Forces India (2011) 0.75
Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies. Immunotargets Ther (2016) 0.75
Vulvar Langerhans cell histiocytosis: a case report. Pan Afr Med J (2014) 0.75
Langerhans Cell Histiocytosis: Diagnosis on Thyroid Aspirate and Review of the Literature. Head Neck Pathol (2015) 0.75
Thyroid Langerhans cell histiocytosis and papillary thyroid carcinoma. Gland Surg (2016) 0.75
Detection of Epstein-Barr Virus DNA in Langerhans Cell Histiocytosis. Jundishapur J Microbiol (2015) 0.75
Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions. PLoS One (2014) 0.75
Cytomegalovirus and Langerhans Cell Histiocytosis: Is There a Link? Iran J Pediatr (2016) 0.75
Persistent pulmonary interstitial emphysema in a case of Langerhans cell histiocytosis. Indian J Radiol Imaging (2014) 0.75
A 36-year-old man with seizures and multiple cystic pulmonary nodules. Chest (2012) 0.75
Proliferative activity and apoptosis of Langerhans histiocytes in eosinophilic granulomas as evaluated by MIB-1 and TUNEL methods. Clin Mol Pathol (1995) 0.75
Suppression subtractive hybridization method for the identification of a new strain of murine hepatitis virus from xenografted SCID mice. Arch Virol (2015) 0.75
Solitary eosinophilic granuloma of mandibular condyle: literature review and report of a rare case. J Maxillofac Oral Surg (2012) 0.75
BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis. Oncoimmunology (2016) 0.75
Current concepts for the diagnosis and management of eosinophilic granuloma of bone. J Orthop Traumatol (2016) 0.75
Clonality in Langerhan's cell histiocytosis. BMJ (1995) 0.75
Eosinophilic granuloma/Langerhans cell histiocytosis: Pediatric neurosurgery update. Surg Neurol Int (2015) 0.75
Langerhans cell histiocytosis of the sternum. Ups J Med Sci (2009) 0.75
Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Mod Pathol (2017) 0.75
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry. Virchows Arch (2011) 0.75
Langerhans-cell histiocytosis (LCH) a presentation of two siblings with two different entities. Springerplus (2015) 0.75
Langerhans Cell Histiocytosis of the Thoracic Spine in an Adult. Korean J Spine (2017) 0.75
Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. Virchows Arch (2017) 0.75
Congenital solid neck mass: a unique presentation of Langerhans cell histiocytosis. Pediatr Radiol (2008) 0.75
Adult Langerhans cell histiocytosis with pulmonary and colorectoanal involvement: a case report. J Med Case Rep (2017) 0.75
Cardiothoracic manifestations of primary histiocytoses. Br J Radiol (2016) 0.75
A rare case of CD1a-negative Langerhans cell histiocytosis of the central nervous system in a child. Clin Case Rep (2017) 0.75
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 4.64
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med (1997) 3.62
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
A simple measure of insulin resistance. Lancet (1995) 3.44
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (1995) 3.38
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia (2009) 3.23
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood (1996) 2.73
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia (2010) 2.65
HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol (1997) 2.59
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia (2007) 2.49
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell (2000) 2.41
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J (1997) 2.06
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A (1996) 1.98
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol (1996) 1.93
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer (1997) 1.82
Development of a highly polymorphic STR marker for identity testing purposes at the human androgen receptor gene (HUMARA). J Forensic Sci (1998) 1.80
The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol (1996) 1.75
cDNA cloning and nucleotide sequence comparison of Chinese hamster metallothionein I and II mRNAs. Nucleic Acids Res (1983) 1.70
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63
Demonstration of an osteoblast defect in two cases of human malignant osteopetrosis. Correction of the phenotype after bone marrow transplant. J Clin Invest (1996) 1.57
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol (2005) 1.56
The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev (1998) 1.55
Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood (1998) 1.55
Physiology and pathophysiology of dendritic cells. Hum Pathol (1997) 1.54
Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci U S A (1980) 1.54
Hematologic malignancies. Curr Opin Hematol (2001) 1.52
Enteric duplications. Thirty-seven cases: a vascular theory of pathogenesis. Am J Dis Child (1971) 1.48
Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens. J Clin Microbiol (2002) 1.46
Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J (2000) 1.44
A single blood culture for confirmation of the diagnosis of neonatal septicemia. Am J Clin Pathol (1972) 1.43
The role of tranexamic acid in the treatment of giant hemangiomas in newborns. Am J Pediatr Hematol Oncol (1993) 1.42
Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol (2001) 1.41
Using granulocyte colony-stimulating factor for neutropenia during neonatal sepsis. Arch Pediatr Adolesc Med (1994) 1.38
ARG tyrosine kinase activity is inhibited by STI571. Blood (2001) 1.35
The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am (1998) 1.33
TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood (1996) 1.33
Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood (1998) 1.31
Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol (2001) 1.28
Histiocytosis syndromes in children. Lancet (1987) 1.26
Renal tumors in the neonatal period. Cancer (1968) 1.25
Coordinate amplification of metallothionein I and II genes in cadmium-resistant Chinese hamster cells: implications for mechanisms regulating metallothionein gene expression. Mol Cell Biol (1985) 1.23
Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia (2004) 1.21
Neonatal small left colon syndrome. Am J Roentgenol Radium Ther Nucl Med (1974) 1.21
Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J Clin Invest (2000) 1.21
X-inactivation analysis in the 1990s: promise and potential problems. Leukemia (1998) 1.20
Professional attitudes toward the autopsy. A survey of clinicians and pathologists. Am J Clin Pathol (1989) 1.20
TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood (1999) 1.19
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene (1996) 1.19
Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia (2002) 1.18
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia (2010) 1.18
PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia (2009) 1.16
Nonhemolytic group B streptococcal infections. J Pediatr (1976) 1.15
An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X. Nucleic Acids Res (1994) 1.15
Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am (1998) 1.14
Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene (2000) 1.14
Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia (2008) 1.14
Chimeric toxins: toxic, disulfide-linked conjugate of concanavalin A with fragment A from diphtheria toxin. Proc Natl Acad Sci U S A (1978) 1.13
Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell (1980) 1.13
Langerhans' cell histiocytosis (histiocytosis X): immunophenotype and growth fraction. Hum Pathol (1993) 1.13
Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS. Leuk Lymphoma (1997) 1.12
Duplications of the alimentary tract: report of three unusual cases associated with bile and pancreatic ducts. Surgery (1972) 1.08
Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood (1996) 1.08
Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant (1997) 1.08
The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet Cytogenet (2001) 1.08
The single-patient room in the NICU: maternal and family effects. J Perinatol (2011) 1.06
The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood (2001) 1.06
Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213. Cancer (1980) 1.04
Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant (2001) 1.04
TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood (1995) 1.04
Molecular biology of acute myeloid leukemia. Semin Oncol (1997) 1.04
Epstein-Barr virus--determined clonality in posttransplant lymphoproliferative disease. Transplantation (1990) 1.04
Clonal evolution in acute myeloid leukemia. Blood (1993) 1.03
The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol (1997) 1.03
Histiocytosis X. Hum Pathol (1983) 1.02
The "analgizer" in a general hospital: a preliminary report. Can Anaesth Soc J (1970) 1.01
Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am (1998) 1.01
Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood (1994) 1.00
Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia (2008) 1.00
Disseminated intravascular and cardiac thrombosis of the neonate. Am J Dis Child (1974) 1.00
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia (2008) 0.99
Transforming properties of the Huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein. J Biol Chem (1999) 0.99
Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc (1993) 0.99
Leprechaunism (Donohue's syndrome): a case report. J Pediatr (1969) 0.98
Acute leukemia in association with Langerhans cell histiocytosis. Med Pediatr Oncol (1994) 0.97
Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics (1995) 0.96
Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). Blood (1982) 0.96